
Using existing drugs to treat cervical cancer before standard treatment could lead to a 35% reduction in the risk of relapse or death, a new study suggests.
Researchers from the UCL Cancer Institute and UCLH looked into whether a short course of induction chemotherapy (IC), where a drug is used to destroy as many cancer cells as possible, before chemoradiation (CRT), could help with this.